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S336 Poster Session IIGy. TBI, ATG 5mg/kg total dose, and cyclophosphamide 40mg/kg
in case of matched related donors, and 60 mg/kg for unrelated or
mismatched donors. In the remaining 12 patients, TBI was replaced
by I.V. Busulfan 3.2 mg/kg/d for 4 days. Eighteen patients were
transplanted using an HLA identical sibling donor, and 22 received
transplant from an unrelated donor. After allo-HSCT, 39 patients
(97.5%) engrafted. In the CR group (n 5 4), after a median fol-
low-up of 5 months (range, 3-31) all patients were still alive in CR
at last follow-up. In the remaining 36 patients, 9 patients developed
acute GVHD $2 with a cumulative incidence at 3 months of 18%
(95%CI, 10-26). At day 90 post HSCT, 23 (64%) patients achieved
hematological CR, and 14 of the 23 remained inCR at last follow-up.
After a median follow-up of 6 months (range, 1-60), the 2-years
probability of OS was 30% (95%CI, 17-52), and the 2-years proba-
bility of PFS was 29% (95%CI, 17-50). The cumulative incidence of
relapse at 1 year was 25% (95%CI, 18-33). Interestingly, none of the
patients who received Busulfan instead of TBI, relapsed. The cumu-
lative incidence of TRM at 3 months and 1 year were 14% (95%CI,
8-20) and 22% (95%CI, 15-29), respectively.
In the multivariate analysis there was a significantly worsened PFS
in patients who received transplant from amismatched donor (HR5
3.6; [95%CI, 1.3-10] p 5 0.01). Also, when considering disease re-
lapse, there was a highly significant impact of the type of RIC regi-
men (in favour of a FLAMSA regimen without TBI (HR 5 0;
[95%CI, 0-0] p\0.0001). A modified FLAMSA regimen incorporat-
ing I.V. Busulfan instead of TBI is likely to allow better long-term
disease control, warranting prospective evaluation.355
RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLAN-
TATION FOR HEMATOLOGICAL MALIGNANCIES: FACTORS IMPACTING
ITS OCCURRENCE AND TREATMENT OPTIONS FOR A BETTER MANAGE-
MENT
Michallet, M., Sobh, M., Morisset, S., Detrait, M., Labussiere, H.,
Ducastelle, S., Barraco, F., Chelghoum, Y., Thomas, X., Nicolini, F.E.
Centre Hospitalier Lyon Sud, Pierre Benite, France
To evaluate the different pre- and post-transplantation factors im-
pacting the relapse occurrence after allo-HSCT, and to evaluate fac-
tors impacting the survival post-relapse including the different
treatment options; we retrospectively studied the occurrence of re-
lapse in 345 patients, 198 (57%) males and 147 (43%) females with
a median age of 43 years (range17-66) who received allo-HSCT at
our institution for hematological malignancies between years 2000
and 2011; 205 (59%) from siblings and 140 (41%) form unrelated
donors. At transplantation, there were 148 (43%) patients in first
complete response or first chronic phase (CR1/CP1), 66 (19%) in
CR2/CP2 and 131 (38%)\CR2/CP2; 206 (60%) patients received
a full intensity conditioning and 139 (40%) a reduced intensity one.
The different patients and transplantations characteristics with p
values will be communicated in the future. After HSCT, 336
(97%) patients engrafted. The cumulative incidence of acute
GVHD$2 at 3 months was 35% (95%CI 32-37); the cumulative in-
cidence of extensive and limited chronic GVHD at one year was the
same 15% (95%CI 13-17). After a median follow-up of 11.4 months
(range 4-129), the median overall survival (OS) for the whole popu-
lation was 19months (range 12-33) with a 2-years probability of 47%
(95%CI 42-53). Eighty eight (25.5%) patients relapsed with a cumu-
lative incidence at one and two years of 19% (95%CI 17-21) and
22% (95%CI 20-24) respectively. After relapse, 65 (74%) patients
were treated [21 (32%) received DLI alone, 21 (32%) chemotherapy
alone, 14 (22%) DLI + chemotherapy and 9 (14%) received other
treatment] and 23 (26%) were not treated due to deadly relapse.
The median OS from relapse was 4 months (range 3-5) and the
one year probability of OS in patients who relapsed was 21% (95%
CI 14-31). The multivariate analysis studying the impact of different
variables on the occurrence of relapse showed a negative impact of
disease status [\CR/CP:HR5 3.9 (2.4-6.7), p5 0.0001], a negative
impact of CMV status [D+R-: HR 5 2.4 [1.2-4.7], p 5 0.009] and
a protective impact of cGVHD [HR 5 0.37 (0.2-0.6), p 5 0.0002].
The multivariate analysis studying the pre- and post-relapse vari-
ables on the survival after relapse showed a positive impact of Major
ABO incompatibility: HR 5 0.39 (0.16-0.9), p 5 0.03], a negative
impact of disease status [\CR/CP: HR 5 2.4 (1.3-4.4), p 5 0.003]and a positive survival outcome in patients receiving DLI with or
without chemotherapy [HR 5 0.5 (0.3-0.8), p 5 0.005].
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MAJOR ABO INCOMPATIBLE BONE MARROW TRANSPLANTATION: EF-
FECT OF ISOHEMAGGLUTININ REDUCTION BY PLASMAPHERESIS
Sheppard, D., Tay, J., McDiarmid, S., Huebsch, L.B., Tokessy, M.,
Hamelin, L., Saidenberg, E., Bredeson, C. The Ottawa Hospital, Ottawa,
ON, Canada
Background: The impact of donor-recipient ABO incompatibility
on BMT outcome remains controversial. While some studies have
found no impact, others have found an increased risk of GVHD
and graft failure and an adverse effect on engraftment and OS.
This variability may be partially explained by the lack of consensus
on the management of ABO incompatibility. A common strategy is
to deplete the product of red cells, although this adversely affects
stem cell yield and there is no agreed upon volume that is safe to in-
fuse.
At the Ottawa Hospital (TOH), recipients of major ABO incom-
patible BMT undergo plasmapheresis using 5% albumin when the
product hematocrit is . 10%. Acceptable titres are 1:4 for Anti-A
and 1:8 for Anti-B. The graft is not manipulated. As manipulation
of the marrow is the more common strategy in North America, the
goal of our study is to review the efficacy and safety of this approach
in ABO incompatible BMT.
Methods:We conducted a retrospective review of all major ABO in-
compatible BMT at TOH over a 10-year period from Jan. 1, 2000 to
Dec. 31, 2010. The primary outcome was time to engraftment. Sec-
ondary outcomes included number of plasmaphereses, transfusion
requirements, clinically significant hemolysis and OS.
Results: 26 pts underwent BMT using a major ABO incompatible
donor. 20 pts were male and the median age was 41(11 – 61) years.
Indications for BMT were AML(n 5 11), ALL(n 5 6), NHL(n 5
3), CML(n5 2) and others(n5 4). 19 pts hadmatched sibling donors
and 7 had unrelated donors - 2 of whom were mismatched at 1 anti-
gen. 20 pts underwent myeloablative and 6 underwent reduced-in-
tensity conditioning.
The median number of plasmaphereses was 1(0 – 4). The median
time to neutrophil engraftment for this cohort was 26(17 – 38) days.
This was not significantly different than 110 pts undergoing BMT
without major ABO incompatibility at TOH during the same period
(21 days; 10 – 60; p 5 0.7). Median platelet engraftment (platelet
count . 20 x 109/L) occurred at day 23.5(18 – not reached) in this
cohort and day 21.5(12 – not reached) in the larger cohort (p 5
0.5). The median number of red cell and platelet transfusions were
6(2 – 47) and 24(4 – 140), respectively. No acute hemolytic transfu-
sion reactions were observed. OS at a maximum of 11 years is 52.8%
for pts undergoing major ABO incompatible BMT vs. 42.7% for the
larger cohort.
Conclusions: As an alternative to RBC depletion, recipient plasma-
pheresis is a safe and effective method of managing donor-recipient
major ABO incompatibility prior to BMT.
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lege of Wisconsin; 2Memorial Sloan-Kettering Cancer Center; 3The
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A. Michallon, CHU de Grenoble; 7American University of Beirut;
8King Faisal Specialist Hospital & Research Center; 9Royal Melbourne
Hospital; 10University of North Carolina; 11University of New Mexico;
12Hospital Universidad Autonoma de Nuevo Leon; 13Nagoya University
Graduate School of Medicine; 14No Institution
Background:TBI as part of the conditioning regimen prior toHCT
is used primarily to eradicate malignancy and to facilitate engraft-
ment. TBI practices vary widely according to several factors, and
Poster Session II S337changes in transplant practices in the last decades also influenced the
decision to use TBI. This study explores the patterns and trends of
TBI use among HCT recipients worldwide.
Methods: 219,341 HCT recipients between 1995 and 2010 regis-
tered with the Center for International Blood and Marrow Trans-
plant Research (CIBMTR) from 596 centers in 52 countries were
analyzed. Subset analysis to investigate changes over time was per-
formed by excluding transplant centers that reported TBI use in all
(N 5 45) or in none (N 5 14,497) of the patients registered during
the period.
Results:TBI was utilized in 10% of autologous and 46% of alloge-
neic HCTs. Among autologous HCT recipients, TBI was most fre-
quently used in: patients of ages 10 to 29 years (10%), chronic
lymphocytic leukemia (56%), Middle East/ Africa (23%) and coun-
tries of medium Human Development Index (HDI) (46%). Among
allogeneic HCT recipients, TBI was most frequently used in: pa-
tients ages 10 to 39 years (45%), acute lymphocytic leukemia
(ALL) (80%), recipients of unrelated donor grafts (55%), Europe
(50%) and in countries with very high HDI. Utilization of TBI-
based conditioning decreased in both autologous (13% to 2%,
p\0.0001) and allogeneic HCTs (53% to 39%, p\0.0001) during
the study period. Decrease in TBI use was observed in all conti-
nents except in Latin America where use of TBI in allogeneic
HCT increased from 15 to 25% of transplants. Also, the drop in
TBI use was observed in all diseases, except in allogeneic HCTs
for ALL (74% to 84%, p\0.0001). Among patients with ALL,
TBI use over time increased in pediatric patients (75% to 91%,
p\0.0001) and recipients of sibling donor grafts (69% to 78%,
p\0.0001).
Discussion: Variations in use of TBI were mainly observed by age,
geographic regions, HDI, cell sources, and disease indications. Use
of TBI decreased significantly over time with exception of allogeneic
HCTs for patients with ALL.358
TREOSULFAN-BASED CONDITIONING FOR UMBILICAL CORD BLOOD RE-
CIPIENTS IS SAFE AND EFFECTIVE: RESULTS FROM AN ONGOING PHASE-
II STUDY
Milano, F.1, Deeg, J.H.1,2, Gutman, J.A.3, Eneida, N.R.4, Delaney, C.1,5
1Fred Hutchinson Cancer Research Center, Seattle, WA; 2University of
Washington School of Medicine, Seattle, WA; 3University of Colorado,
Denver, CO; 4Oregon Health & Science University, Portland, OR; 5Uni-
versity of Washington School of Medicine, Seattle, WA
Backgrounds:Treosulfan (Treo) is an immuno-suppressive and cy-
totoxic alkylating agent recently introduced as a conditioning agent
for hematopoietic cell transplantation (HCT). Previous studies have
evaluated the use of Treo-based conditioning regimens for conven-
tional donorHCT, however, there is minimal experience using Treo
in umbilical cord blood transplantation (CBT).
Methods: Between March 2009 and July 2011, 25 consecutive CBT
recipients were enrolled in a prospective phase II study at Fred
Hutchinson Cancer Research Center. All patients received intrave-
nous (IV) fludarabine, 30 mg/m2 on days -6 to -2 (total dose: 150
mg/m2), Treo 14 g/m2 IV on days -6, -5, and -4 (total dose: 42
g/m2) and a single dose of 2 Gy of total body irradiation (TBI) on
day -2 before HCT. Graft Versus Host Disease (GVHD) prophy-
laxis consisted of cyclosporine and MMF. Engraftment, non-relapse
mortality (NRM) and acute and chronic GVHD were calculated us-
ing cumulative incidence (CI) rates. Relapse-free survival (RFS) and
overall survival (OS) were determined using Kaplan-Meier
estimates.
Results: All but 2 patients received double CBT, and the median
dose of nucleated cells was 3.8 (range, 2.4-11.2) x 107/Kg. The me-
dian age was 48 (range, 5-63) years and weight 76 (range, 17-114)
Kg. Eighteen patients (72%) had acute leukemia, 5 (20%) MDS
and 2 CML (8%). Four patients (16%) had received a previous al-
logeneic and 1 a previous autologous HCT. Fifteen patients (60%)
had minimal residual disease, and 6 (24%) were in second complete
remission (CR2). The median follow-up of survivors was 435 (range
73-947) days. Median time of neutrophil recovery was 23 (range,
13-89) days, with a CI of engraftment of 92% (95% CI, 72-97%).
Two patients experienced primary graft failure, and one of these re-
ceived a second HLA-haploidentical HCT. The 2-year probabili-ties of OS and RFS were 61.7% (95% CI, 37-79%) and 54%
(95% CI, 28-74%), respectively. The CI of NRM at 2 years was
18% (95% CI, 5-37%), and relapse incidence 21% (6-43%). Eight
patients (32%) died, relapse and multiorgan failure being the most
common causes (n 5 6). The CI of grades II-IV and III-IV acute
GVHD was 64% (95% CI, 42-80) and 20% (95% CI, 7-38%), re-
spectively. Chronic incidence GVHD at 1 year was 28% (95% CI,
10-45%).
Conclusions: Data from this trial suggest that Treo-based condi-
tioning regimens are safe and effective in CBT. Treo represents
a promising non-TBI based myeloablative regimen for patients un-
dergoing CBT.359
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Background: The effect of sex mismatch on outcome in allogeneic
hematopoietic stem cell transplantation (HSCT) has been studied
with controversial results. Possible effect of Y chromosome mis-
match in graft-versus-host (GVH) direction, i.e. HSCT from a fe-
male donor to a male recipient has been identified in previous
studies. HSCT from a Japanese donor to a Japanese recipient is re-
ported to have lower incidence of severe acute GVHD and lower
mortality which may derive from their genetic homogeneity back-
ground. Therefore, the effect of Y chromosome mismatch may be
clearer in our population.
Purpose:The aim of this study is to assess the effect of sex mismatch
on outcome in allogeneic HSCT.
Method: Sixty-four hundred twenty-one adult patients (3,768
males and 2,653 females) with a median age of 45-year-old (range
16-82) who underwent allogeneic HSCT for the first time for he-
matological malignancies between January, 2006 and December,
2009 in Japan were included in this study. 4,121 patients (64%)
had acute leukemia as underlying disease. Bone marrow transplan-
tation (BMT) (62%), peripheral blood stem cell transplantation
(PBSCT) (21%), and cord blood transplantation (CBT) (17%)
were all included. Sixty-three percent were from unrelated donors.
Data were collected and analyzed retrospectively using the trans-
plant outcome database of Japan Society for Hematopoietic Cell
Transplantation.
Results: Proportion of female to male donor-recipient pairs (F to
M mismatch) were 23% (n 5 1,500) (53%, n 5 3,401 for sex-
matched pairs and 24%, n 5 1,520 for male to female pairs). Pro-
portion of peripheral blood (24% vs. 19%) and cord blood (23% vs.
16%) was larger in F to M mismatch (p\0.001). More patients re-
ceived human leukocyte antigen (HLA) -A, -B, and -DR serological
mismatched graft in F to M mismatch (35% vs. 29%, p\0.01). In
univariate comparison, the probabilities of overall survival (OS)
was significantly lower in F to M mismatch (p\0.001). Although
the effect of F to M mismatch on OS was more obvious in HLA-
matched HSCT (p 5 0.0033), it was also observed in HLA-mis-
matched HSCT (p 5 0.017). The probabilities of OS in F to M
mismatch was significantly lower in unrelated BMT (p 5 0.011)
and CBT (p 5 0.019). However, there was no significantly differ-
ence among related BMT (p 5 0.087) and PBSCT (p 5 0.54) ac-
cording to the presence of F to M mismatch, even if HSCT were
limited to HLA-matched.
Conclusion: Female to male sex mismatch has a significant impact
on the outcome of HSCT.
